Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study That Tests AD109 in Patients Taking GLP-1 Drugs

ClinicalTrials.gov ID: NCT06400615

Public ClinicalTrials.gov record NCT06400615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

Study identification

NCT ID
NCT06400615
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Apnimed
Industry
Enrollment
40 participants

Conditions and interventions

Conditions

Interventions

  • AD109 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 19, 2024
Primary completion
Dec 25, 2024
Completion
Dec 25, 2024
Last update posted
Feb 18, 2025

2024

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Pinnacle Research Group, LLC Anniston Alabama 36207
Clinical Neuroscience Solutions, Inc Jacksonville Florida 32256
Monroe Biomedical Research Monroe North Carolina 28112
Clinical Neuroscience Solutions, Inc Memphis Tennessee 38119

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06400615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 18, 2025 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06400615 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →